151 related articles for article (PubMed ID: 37000716)
41. Estimated impact of the pneumococcal conjugate vaccine on pneumonia mortality in South Africa, 1999 through 2016: An ecological modelling study.
Kleynhans J; Tempia S; Shioda K; von Gottberg A; Weinberger DM; Cohen C
PLoS Med; 2021 Feb; 18(2):e1003537. PubMed ID: 33591995
[TBL] [Abstract][Full Text] [Related]
42. Population genetic structure, antibiotic resistance, capsule switching and evolution of invasive pneumococci before conjugate vaccination in Malawi.
Chaguza C; Cornick JE; Andam CP; Gladstone RA; Alaerts M; Musicha P; Peno C; Bar-Zeev N; Kamng'ona AW; Kiran AM; Msefula CL; McGee L; Breiman RF; Kadioglu A; French N; Heyderman RS; Hanage WP; Bentley SD; Everett DB
Vaccine; 2017 Aug; 35(35 Pt B):4594-4602. PubMed ID: 28711389
[TBL] [Abstract][Full Text] [Related]
43. Cost effectiveness of pneumococcal vaccination among Dutch infants: economic analysis of the seven valent pneumococcal conjugated vaccine and forecast for the 10 valent and 13 valent vaccines.
Rozenbaum MH; Sanders EA; van Hoek AJ; Jansen AG; van der Ende A; van den Dobbelsteen G; Rodenburg GD; Hak E; Postma MJ
BMJ; 2010 Jun; 340():c2509. PubMed ID: 20519267
[TBL] [Abstract][Full Text] [Related]
44. Impact of pneumococcal conjugate vaccine on invasive pneumococcal disease in children under 5 years of age in the Czech Republic.
Kozakova J; Krizova P; Maly M
PLoS One; 2021; 16(2):e0247862. PubMed ID: 33635933
[TBL] [Abstract][Full Text] [Related]
45. Colonization with 19F and other pneumococcal conjugate vaccine serotypes in children in St. Louis, Missouri, USA.
McFarland M; Szasz TP; Zhou JY; Motley K; Sivapalan JS; Isaacson-Schmid M; Todd EM; Hogan PG; Fritz SA; Burnham CD; Hoffmann S; Morley SC
Vaccine; 2017 Aug; 35(34):4389-4395. PubMed ID: 28687405
[TBL] [Abstract][Full Text] [Related]
46. Impact of infant pneumococcal vaccination on invasive pneumococcal diseases in France, 2001-2006.
Lepoutre A; Varon E; Georges S; Gutmann L; Lévy-Bruhl D
Euro Surveill; 2008 Aug; 13(35):. PubMed ID: 18761883
[TBL] [Abstract][Full Text] [Related]
47. [Epidemiological features of invasive pneumococcal disease before and after the introduction of pneumococcal conjugate vaccine in Gran Canaria (Canary Islands)].
Artiles F; Horcajada I; Cañas AM; Alamo I; Bordes A; González A; Santana M; Lafarga B
Enferm Infecc Microbiol Clin; 2009 Jan; 27(1):14-21. PubMed ID: 19217998
[TBL] [Abstract][Full Text] [Related]
48. Population-based impact of pneumococcal conjugate vaccine in young children.
Poehling KA; Lafleur BJ; Szilagyi PG; Edwards KM; Mitchel E; Barth R; Schwartz B; Griffin MR
Pediatrics; 2004 Sep; 114(3):755-61. PubMed ID: 15342850
[TBL] [Abstract][Full Text] [Related]
49. Declining serotype coverage of new pneumococcal conjugate vaccines relating to the carriage of Streptococcus pneumoniae in young children.
Tocheva AS; Jefferies JM; Rubery H; Bennett J; Afimeke G; Garland J; Christodoulides M; Faust SN; Clarke SC
Vaccine; 2011 Jun; 29(26):4400-4. PubMed ID: 21504773
[TBL] [Abstract][Full Text] [Related]
50. Change in Pneumococcus Serotypes but not Mortality or Morbidity in Pre- and Post-13-Valent Polysaccharide Conjugate Vaccine Era: Epidemiology in a Pediatric Intensive Care Unit over 10 Years.
Hon KL; Chan KH; Ko PL; Cheung MHY; Tsang KYC; Chan LCN; Chan RWY; Leung TF; Ip M
J Trop Pediatr; 2018 Oct; 64(5):403-408. PubMed ID: 29126217
[TBL] [Abstract][Full Text] [Related]
51. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
52. Indirect effects of 13-valent pneumococcal conjugate vaccine on pneumococcal carriage in children hospitalised with acute respiratory infection despite heterogeneous vaccine coverage: an observational study in Lao People's Democratic Republic.
Chan J; Lai JYR; Nguyen CD; Vilivong K; Dunne EM; Dubot-Pérès A; Fox K; Hinds J; Moore KA; Nation ML; Pell CL; Xeuatvongsa A; Vongsouvath M; Newton PN; Mulholland K; Satzke C; Dance DAB; Russell FM;
BMJ Glob Health; 2021 Jun; 6(6):. PubMed ID: 34108146
[TBL] [Abstract][Full Text] [Related]
53. Pneumococcal conjugate vaccination and nasopharyngeal acquisition of pneumococcal serotype 19A strains.
van Gils EJ; Veenhoven RH; Hak E; Rodenburg GD; Keijzers WC; Bogaert D; Trzcinski K; Bruin JP; van Alphen L; van der Ende A; Sanders EA
JAMA; 2010 Sep; 304(10):1099-106. PubMed ID: 20823436
[TBL] [Abstract][Full Text] [Related]
54. Cost-effectiveness analysis of the introduction of the pneumococcal conjugate vaccine (PCV-13) in the Egyptian national immunization program, 2013.
Sibak M; Moussa I; El-Tantawy N; Badr S; Chaudhri I; Allam E; Baxter L; Abo Freikha S; Hoestlandt C; Lara C; Hajjeh R; Munier A
Vaccine; 2015 May; 33 Suppl 1():A182-91. PubMed ID: 25919159
[TBL] [Abstract][Full Text] [Related]
55. Effect of pneumococcal conjugate vaccine on prevalence of otitis media with effusion among children in Vietnam.
Toizumi M; Satoh C; Quilty BJ; Nguyen HAT; Madaniyazi L; Le LT; Ng CFS; Hara M; Iwasaki C; Takegata M; Kitamura N; Nation ML; Satzke C; Kumai Y; Do HT; Bui MX; Mulholland K; Flasche S; Dang DA; Kaneko K; Yoshida LM
Vaccine; 2022 Aug; 40(36):5366-5375. PubMed ID: 35934579
[TBL] [Abstract][Full Text] [Related]
56. Imputing the Direct and Indirect Effectiveness of Childhood Pneumococcal Conjugate Vaccine Against Invasive Pneumococcal Disease by Surveying Temporal Changes in Nasopharyngeal Pneumococcal Colonization.
Nzenze SA; Madhi SA; Shiri T; Klugman KP; de Gouveia L; Moore DP; Karstaedt AS; Tempia S; Nunes MC; von Gottberg A
Am J Epidemiol; 2017 Aug; 186(4):435-444. PubMed ID: 28482004
[TBL] [Abstract][Full Text] [Related]
57. Non-vaccine serotype pneumococcal carriage in healthy infants in South Africa following introduction of the 13-valent pneumococcal conjugate vaccine.
Skosana Z; Von Gottberg A; Olorunju S; Mohale T; Du Plessis M; Adams T; Mbelle N
S Afr Med J; 2021 Feb; 111(2):143-148. PubMed ID: 33944725
[TBL] [Abstract][Full Text] [Related]
58. Public health impact of pneumococcal conjugate vaccine infant immunization programs: assessment of invasive pneumococcal disease burden and serotype distribution.
Izurieta P; Bahety P; Adegbola R; Clarke C; Hoet B
Expert Rev Vaccines; 2018 Jun; 17(6):479-493. PubMed ID: 29241390
[TBL] [Abstract][Full Text] [Related]
59. Reduced nontypeable Haemophilus influenzae lower airway infection in children with chronic endobronchial suppuration vaccinated with the 10-valent pneumococcal H. influenzae protein D conjugate vaccine.
Hare KM; Smith-Vaughan HC; Leach AJ; Pizzutto SJ; McCallum GB; Chang AB
Vaccine; 2018 Mar; 36(13):1736-1742. PubMed ID: 29478754
[TBL] [Abstract][Full Text] [Related]
60. Assessing the impact of pneumococcal conjugate vaccines on invasive pneumococcal disease using polymerase chain reaction-based surveillance: an experience from South Africa.
Tempia S; Wolter N; Cohen C; Walaza S; von Mollendorf C; Cohen AL; Moyes J; de Gouveia L; Nzenze S; Treurnicht F; Venter M; Groome MJ; Madhi SA; von Gottberg A
BMC Infect Dis; 2015 Oct; 15():450. PubMed ID: 26496761
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
